HIV drug sales rescue GSK's second quarter
This article was originally published in Scrip
Executive Summary
In the first full quarter since the closure of its mega three-part transaction with Novartis, GlaxoSmithKline beat analyst expectations. In particular there were "stand out" sales of its HIV drugs Tivicay and Triumeq, validating GSK's decision earlier this year to hang on to its stake in HIV company ViiV Healthcare.